Equities research analysts at HC Wainwright increased their Q1 2025 earnings estimates for Atossa Therapeutics in a note ...

And we're going to take some Q&A after that. So with the highlights ... And this is a normal situation with the instability that was with Atos during the year of 2024. If we deep dive between ...

Atossa Therapeutics Inc (ATOS) reports reduced operating expenses and promising developments in its lead program, Z-endoxifen, while maintaining a strong cash position.

No dividends were paid to Atos SE shareholders in 2024. The €18 million cash out (€35 million in 2023) corresponded to taxes withheld on internal dividend distributions and to dividends paid ...

March 5 (Reuters) - Atos (ATOS.PA), opens new tab will launch a reverse stock split, likely to take effect by May 1, CEO Philippe Salle said on Wednesday, as the French group seeks to restore ...

Atos today shared a drop in revenues in Q3 FY24, mostly due to the global market slowdown during a period of transformation for the company. Q3 revenues were down 4.4 per cent to €2.3bn (£1.9bn), ...

Atos' first half of 2023 isn't looking bright after its Q2 financial report which highlighted a plummeting operating income and caused shares price to drop by 20 per cent. The report showed operating ...

Then Heather will discuss our full year 2024 financial results, and we will conclude with a Q&A session. However, before we provide those updates I just want to take a moment to talk about the ...